Compare ALLR & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALLR | GSIW |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5M | 24.2M |
| IPO Year | 2021 | 2022 |
| Metric | ALLR | GSIW |
|---|---|---|
| Price | $1.21 | $15.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 85.7K | 50.3K |
| Earning Date | 05-15-2026 | 08-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $320,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $0.05 |
| 52 Week High | $1.84 | $38.55 |
| Indicator | ALLR | GSIW |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 46.41 |
| Support Level | $1.01 | $15.24 |
| Resistance Level | $1.27 | $18.03 |
| Average True Range (ATR) | 0.10 | 1.51 |
| MACD | -0.03 | 0.24 |
| Stochastic Oscillator | 16.25 | 59.60 |
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Garden Stage Ltd, through its subsidiaries is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; asset management services; investment advisory services; due diligence services; and introduction and referral services. The company operates in a single segment and derives all of its revenue from Hong Kong.